Logo image of SYRE

SPYRE THERAPEUTICS INC (SYRE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SYRE - US00773J2024 - Common Stock

24.26 USD
+0.79 (+3.37%)
Last: 11/21/2025, 8:01:44 PM
24.26 USD
0 (0%)
After Hours: 11/21/2025, 8:01:44 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SYRE. SYRE was compared to 533 industry peers in the Biotechnology industry. SYRE has a great financial health rating, but its profitability evaluates not so good. SYRE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SYRE has reported negative net income.
In the past year SYRE has reported a negative cash flow from operations.
SYRE had negative earnings in each of the past 5 years.
In the past 5 years SYRE always reported negative operating cash flow.
SYRE Yearly Net Income VS EBIT VS OCF VS FCFSYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.19%, SYRE is in the better half of the industry, outperforming 63.93% of the companies in the same industry.
The Return On Equity of SYRE (-40.17%) is better than 71.59% of its industry peers.
Industry RankSector Rank
ROA -34.19%
ROE -40.17%
ROIC N/A
ROA(3y)-83.73%
ROA(5y)-72.22%
ROE(3y)-110.99%
ROE(5y)-93.85%
ROIC(3y)N/A
ROIC(5y)N/A
SYRE Yearly ROA, ROE, ROICSYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

SYRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRE Yearly Profit, Operating, Gross MarginsSYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

SYRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SYRE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SYRE has more shares outstanding
There is no outstanding debt for SYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SYRE Yearly Shares OutstandingSYRE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SYRE Yearly Total Debt VS Total AssetsSYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SYRE has an Altman-Z score of 10.18. This indicates that SYRE is financially healthy and has little risk of bankruptcy at the moment.
SYRE has a better Altman-Z score (10.18) than 82.99% of its industry peers.
There is no outstanding debt for SYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.18
ROIC/WACCN/A
WACC8.7%
SYRE Yearly LT Debt VS Equity VS FCFSYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 11.26 indicates that SYRE has no problem at all paying its short term obligations.
The Current ratio of SYRE (11.26) is better than 85.42% of its industry peers.
SYRE has a Quick Ratio of 11.26. This indicates that SYRE is financially healthy and has no problem in meeting its short term obligations.
SYRE has a better Quick ratio (11.26) than 85.42% of its industry peers.
Industry RankSector Rank
Current Ratio 11.26
Quick Ratio 11.26
SYRE Yearly Current Assets VS Current LiabilitesSYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.81% over the past year.
The Revenue for SYRE has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.77% on average over the next years.
SYRE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y32.57%
EPS Next 2Y10.12%
EPS Next 3Y6.8%
EPS Next 5Y4.77%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SYRE Yearly Revenue VS EstimatesSYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2030 2031 2032 200M 400M 600M 800M
SYRE Yearly EPS VS EstimatesSYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SYRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRE Price Earnings VS Forward Price EarningsSYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRE Per share dataSYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.12%
EPS Next 3Y6.8%

More info and screens

0

5. Dividend

5.1 Amount

SYRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPYRE THERAPEUTICS INC

NASDAQ:SYRE (11/21/2025, 8:01:44 PM)

After market: 24.26 0 (0%)

24.26

+0.79 (+3.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners104.27%
Inst Owner ChangeN/A
Ins Owners8.7%
Ins Owner Change-7.01%
Market Cap1.88B
Revenue(TTM)N/A
Net Income(TTM)-208.02M
Analysts88.42
Price Target53.69 (121.31%)
Short Float %17.57%
Short Ratio13.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.81%
Min EPS beat(2)-61.73%
Max EPS beat(2)20.11%
EPS beat(4)2
Avg EPS beat(4)-7.8%
Min EPS beat(4)-61.73%
Max EPS beat(4)20.11%
EPS beat(8)2
Avg EPS beat(8)-279.27%
EPS beat(12)5
Avg EPS beat(12)-182.95%
EPS beat(16)6
Avg EPS beat(16)-139.5%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.06%
PT rev (3m)-3.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.64
P/tB 3.64
EV/EBITDA N/A
EPS(TTM)-2.33
EYN/A
EPS(NY)-3.33
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS0
BVpS6.67
TBVpS6.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.19%
ROE -40.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.73%
ROA(5y)-72.22%
ROE(3y)-110.99%
ROE(5y)-93.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.26
Quick Ratio 11.26
Altman-Z 10.18
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
EPS Next Y32.57%
EPS Next 2Y10.12%
EPS Next 3Y6.8%
EPS Next 5Y4.77%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y16.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.99%
EBIT Next 3Y-5.1%
EBIT Next 5Y-10.76%
FCF growth 1Y-57.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.55%
OCF growth 3YN/A
OCF growth 5YN/A

SPYRE THERAPEUTICS INC / SYRE FAQ

What is the ChartMill fundamental rating of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SYRE.


What is the valuation status for SYRE stock?

ChartMill assigns a valuation rating of 0 / 10 to SPYRE THERAPEUTICS INC (SYRE). This can be considered as Overvalued.


Can you provide the profitability details for SPYRE THERAPEUTICS INC?

SPYRE THERAPEUTICS INC (SYRE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SPYRE THERAPEUTICS INC?

The Earnings per Share (EPS) of SPYRE THERAPEUTICS INC (SYRE) is expected to grow by 32.57% in the next year.